Human mumps IgG ELISA kit is a procedure designed for detecting in-vitro quantitative amounts of human IgG antibodies against mumps virus (mumps-IgG) using serum and plasma. This assay has a minimum analytical sensitivity limit of 1.18 U/ml.
Mumps is highly contagious viral disease which usually spreads quickly among people living in close proximity. It is a linear negative sense, single stranded enveloped RNA virus, which can be transmitted by respiratory droplets or even direct contact with an infected individual. Mumps virus has only been infect and spread amongst humans. It can be prevented by infection of two doses of the mumps vaccine, this is included in the immunisation program for many developed countries. It is often give in combination with measles, rubella and varicella vaccine. The identification of mumps in the laboratory is usually carried out by detecting the infectious agent itself or through the identification of virus-specific antibodies. Besides the classical methods such as fixation, neutralisation and hemagglutination tests, there are now some modern procedures like enzyme immunoassay, radio immunoassay and immunofluorescence which are routinely being used.
MUMPS IGG ELISA KIT CONTENT
All reagents supplied need to be stored at 2 °C – 8 °C, unopened reagents will retain reactivity until expiration date. Do not use reagents beyond this date.
- Mumps antigen coated microtiter strips.
- Cut-Off Standard (Calibrator B).
- Positive Control (Calibrator D).
- Negative Control (Calibrator A).
- Weak Positive Control (Calibrator C).
- Enzyme Conjugate.
- Sample Diluent.
- TMB Substrate.
- Washing Buffer (10x).
- Stop Solution.
The minimum detection sensitivity level of IgG antibodies to mumps (mumps-IgG) using current human mumps virus IgG ELISA kit was 1.18 U/ml. The dynamic range for this assay is 1.0 – 150.0 U/ml.
– Mumps ELISA: IgG
– Intra-Assay-Precision: 8.9 %
– Inter-Assay-Precision: 7.8 %
– Inter-Lot-Precision: 1.3 – 13.8 %
– Analytical Sensitivity: 1.28 U/mL
– Recovery: 72 – 101 %
– Linearity: 82 – 130 %
– Cross-Reactivity: No cross-reactivity to Varicella Zoster and Measles.
– Interferences: No interferences to triglycerides up to 5.0 mg/mL, hemoglobin up to 8.0 mg/mL and bilirubin up to 0.3 mg/mL.
– Clinical Specificity: 88 %
– Clinical Sensitivity: 100 %
- Mumps virus infection in vaccinated patients can be detected by an increase in specific IgG antibodies to high titres: a retrospective study. Epidemiol Infect. (2014) 142 (11): 2388-96. Borgmann S., et al.
- Seropositivity rates for measles, mumps, and rubella IgG and costs associated with testing and revaccination. Clin Vaccine Immunol. (2013) 20 (3): 443-5. Shirts B.H., et al.
- Detection of IgG class antibodies to measles, mumps, rubella, and varicella-zoster virus using a multiplex bead immunoassay. Diagn Microbiol Infect Dis. (2010) 67 (4): 346-9. Dhiman N., et al.
- Avidity of IgG antibodies against mumps, parainfluenza 2 and Newcastle disease viruses after mumps infection. J Virol Methods. (1986) 14 (1): 1-7. Lehtonen O.P. and Meurman O.H.
- Detection of measles, mumps, and rubella viruses. Methods Mol Biol. (2011) 665: 183-93. Tipples G. and Hiebert J.
- Full Name: Mumps IgG ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Plasma
- Sensitivity: 1.18 U/ml